SARS-CoV-2 Main Protease Inhibitors: Structure-Based Enhancement to Anti-Viral Pre-Clinical GC376 Encourages Further Development.

MLA

Perry, Elliot D., et al. “SARS-CoV-2 Main Protease Inhibitors: Structure-Based Enhancement to Anti-Viral Pre-Clinical GC376 Encourages Further Development.” Journal of Computational Biophysics & Chemistry, vol. 22, no. 4, June 2023, pp. 383–99. EBSCOhost, https://doi.org/10.1142/S273741652350014X.

APA

Perry, E. D., Chapman, S., & Xu, Y.-Z. (2023). SARS-CoV-2 Main Protease Inhibitors: Structure-Based Enhancement to Anti-Viral Pre-Clinical GC376 Encourages Further Development. Journal of Computational Biophysics & Chemistry, 22(4), 383–399. https://doi.org/10.1142/S273741652350014X

Chicago

Perry, Elliot D, Simon Chapman, and Yao-Zhong Xu. 2023. “SARS-CoV-2 Main Protease Inhibitors: Structure-Based Enhancement to Anti-Viral Pre-Clinical GC376 Encourages Further Development.” Journal of Computational Biophysics & Chemistry 22 (4): 383–99. doi:10.1142/S273741652350014X.